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The possible cytotoxic effects of three new generation oxazaphosphorines, D-17272 (mafosfamide cyclohexyla-
mine salt), D-18864 (4-hydro-peroxy-cyclophosphamide) and D-19575 (β-D-glucose-isophosphoramide mustard), 
on human acute lymphoblastic leukemia MOLT-4 cells were studied. The infl uence of these agents on the leukemic 
cells was analyzed, using the in vitro spectrophotometric MTT test and Beckman Coulter method. The cell viability, 
as well as the cell size and count, were determined. The patterns of temporary changes in the analyzed parameters 
were dependent on the agent tested and its dose, and the time interval after the oxazaphosphorine application. The 
various MOLT-4 cell responses to the action of  D-18864, D-17272 and D-19575 were shown. 
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INTRODUCTION
Oxazaphosphorines belong to alkylating che-
motherapeutic drugs. The development of new 
oxazaphosphorine agents is of key importance 
to improve their therapeutic index. Several oxa-
zaphosphorine derivatives have recently been 
synthesized and tested (BROCK and POHL, 2000; 
ENGEL et al., 2000; ZHANG et al., 2005a, 2005b; 
LIANG et al., 2007; GIRAUD et al., 2010; MAZUR et 
al., 2011).
The effects of the new generation oxazapho-
sphorines on hematopoietic cells have been inve-
stigated in preclinical studies (ASTA Medica, 1999; 
MAZUR et al., 2008a) and clinical trials (BRIASOULIS 
et al., 2000; VAN DEN BENT et al., 2003; GIACCONE 
et al., 2004; SHIMIZU et al., 2010). However, avai-
lable information on the infl uence of oxazapho-
sphorines on human leukemic cells is still scar-
ce (STYCZYŃSKI et al., 2002a, 2002b; MAZUR et al., 
2009, 2010; OPYDO-CHANEK et al., 2010). 
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The present study was undertaken to compare 
possible cytotoxic effects of three new generation 
oxazaphosphorine agents, D-17272 (mafosfamide 
cyclohexylamine salt), D-18864 (4-hydro-pero-
xy-cyclophosphamide) and D-19575 (β-D-gluco-
se-isophosphoramide mustard), on human acute 
lymphoblastic leukemia MOLT-4 cells. The tempo-
rary changes in the leukemic cell viability, and in 
their size and count, were analyzed.
MATERIALS AND METHODS
Cells
Human acute lymphoblastic leukemia MOLT-4 
cells (European Collection of Cell Culture, ECACC, 
Sigma Aldrich, Catalogue No. 85011413) were 
maintained in RPMI 1640 (Gibco BRL Life Tech-
nologies) supplemented with 10% fetal calf serum 
(GIBCO BRL Life Technologies), 2 mM L-gluta-
mine (Sigma Aldrich), and antibiotic antimycotic 
solution (Sigma Aldrich) containing 20 units of 
penicillin, 20 μg streptomycin and 0.05 μg am-
photericin B. MOLT-4 cells were passaged every 
third day. The cells grew expotentially at 37°C in 
a 5% CO2 atmosphere (HERAcell incubator, Ken-
droLab). The cultures were periodically tested for 
Mycoplasma infection. 
Chemicals
Mafosfamide cyclohexylamine salt (D-17272, CAS 
No. 84210-80-0), 4-hydro-peroxy-cyclophosphami-
de (D-18864, CAS No. 39800-16-3) and glufosfami-
de (D-19575, β-D-glucose-isophosphoramide mu-
stard, CAS No. 132682-98-5) were obtained from 
NIOMECH (Bielefeld, Germany). D-17272, D-18864 
and D-19575 were dissolved in aqua pro injectione 
(Polpharma). All the solutions were freshly prepa-
red directly before treatment of the MOLT-4 cells. 
Agent doses and cell treatment
After diluting the cell suspension to a density of 
15x104 cells/ml medium, MOLT-4 cells were sub-
jected to 30-min exposure to the oxazaphospho-
rine agent. D-18864 was applied at a dose of 10 
μg/ml medium, D-19575 at a dose of 100 μg/ml 
medium, and D-17272 at doses of 10 μg/ml and 
100 μg/ml medium. The control material consisted 
of untreated MOLT-4 cells. After 30-min treatment 
with the oxazaphosphorine agent, MOLT-4 cells 
were centrifuged for 10 min at 1000 rpm and the 
supernatant was discarded. Then the cells were 
washed in 2 ml of PBS (BioMed) and pelleted by 
centrifugation for 7 min. The wash and centrifu-
gation were repeated once more and the cells were 
resuspended in the complete RPMI 1640 medium. 
Spectrophotometric MTT assay
The in vitro MTT test was designed for spectropho-
tometric determination of the viability of cell popu-
lations. MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-di-
phenyl tetrazolium bromide) is the key component 
used in MTT assay. In viable, metabolically active 
cells, the tetrazolium ring is cleaved, yielding for-
mazan crystals. Alterations in the metabolic ac-
tivity of cell populations result in a concomitant 
change in the amount of formazan formed.
Protocol for in vitro MTT assay
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazo-
lium bromide (Sigma-Aldrich) was dissolved in 
RPMI 1640 medium, at a concentration of 5 mg/
ml, and fi ltered through a 0.2 μm fi lter. 100 μl of 
the yellow MTT solution was added to each well of 
a 24-well plate, containing 1 ml of the cell suspen-
sion, and the cells were incubated at 37°C in 5% 
CO2. Blank solution was prepared according to the 
above procedure using complete medium without 
cells. After the three-hour incubation period, the 
resulting formazan crystals were dissolved using 1 
ml of acidifi ed isopropanol (0.05 N HCl in absolute 
isopropanol). Absorbance of the obtained purple 
solution was measured at a wavelength of 570 nm 
using a Pharmacia Ultrospec III spectrophotome-
ter (Pharmacia). The optical density of formazan 
solution was presented as the mean value ± stan-
dard deviation. The extent of MTT conversion in 
cells was also expressed as a percentage of the 
control value.
Cell size and count analysis
Samples of MOLT-4 cell suspension were taken 
from fl asks and immediately diluted in ISOTON 
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II (Beckman Coulter fi ltered electrolyte solution 
based on 0.9 % saline). 500 μl of the cell suspen-
sion was added to 4.5 ml of ISOTON II. After the 
dilution of MOLT-4 cell suspension, individual 
leukemic cells were measured using a Z2 Coulter 
counter (Beckman Coulter, USA). The cell count 
and cell volume distributions for MOLT-4 cells 
were obtained using the counter equipped with a 
100 μm diameter orifi ce. The fl ow rate was 500 
μl / 12.5 sec. The range established for cell mea-
surement was 65.4 – 3674 fl  (5.0 – 19.1 μm). The 
cell count, diameter and volume were analyzed at 
645.6 – 3674 fl  (10.7 – 19.1 μm). The instrument 
was calibrated using 10 μm diameter latex beads 
(Beckman Coulter CC size standard). The mean 
and median cell volumes, modal peak and the 
mean cell diameter, as well as the cell count, were 
analyzed using Z2 AccuComp software (Beckman 
Coulter, USA). The cell count was presented as 
the mean value ± standard deviation.
Statistical evaluation
Statistical signifi cance of alterations in the optical 
density of formazan and the cell count was eva-
luated by the analysis of variance and Duncan’s 
new multiple range test.
RESULTS
The infl uence of the new generation oxazapho-
sphorines on the MOLT-4 cell viability (Table 1, 
Fig.1), the cell size (Table 2, Fig. 2) and the cell 
count (Table 3) was shown. The different patter-
ns of temporary changes in the analyzed para-
meters were observed at 24h and 48h after the 
application of D-17272, D-18864 and D-19575. 
The effects of the oxazaphosphorines appeared 
to be dependent on the compound tested and its 
dose, and the time interval after the treatment of 
MOLT-4 cells with these alkylating agents (Table 
1, 2, 3; Fig. 1, 2). 
DISCUSSION
The results of the present study have demon-
strated the different cytotoxic effects of the three 
oxazaphosphorines, D-17272, D-18864 and D-
19575, on the human acute lymphoblastic leuke-
Experimental group
Time intervals after cell exposure to oxazaphosphorines
24h 48h
   No.          Agent given            Agent dose
Optical density of formazan (x10-3)
Mean ± SD Mean ± SD
I D-18864     10 μg/ml   2, 3, 4, 5, 48h  18.08 ± 0.90
    2, 3, 4, 5, 24h
    6.50 ± 0.55
II D-17272     10 μg/ml   1, 3, 4, 5, 48h  29.58 ± 1.93
    1, 3, 4, 5, 24h 
  15.17 ± 1.17
III D-17272   100 μg/ml   1, 2, 4, 5, 48h  13.67 ± 2.88
    1, 2, 4, 5, 24h 
    1.83 ± 0.41
IV D-19575   100 μg/ml   1, 2, 3, 5, 48h  52.08 ± 3.80
    1, 2, 3, 5, 24h
101.50 ± 2.58
V Control   1, 2, 3, 4, 48h  55.92 ± 1.51
    1, 2, 3, 4, 24h
116.42 ± 0.90
Statistically signifi cant differences at p<0.05
Differences between groups: different from Group I – 1; Group II – 2; Group III – 3; Group IV – 4; 
Group V – 5.
Differences within each group: different from 24h – 24h; 48h – 48h; 72h – 72h.
TABLE 1. The optical density of formazan solution determined in MOLT-4 cells following their exposure to the oxazaphospho-
rine agents. The metabolic activity and cell viability are correlated with the amount of formazan formed.
42 Opydo-Chanek et al.
Fig. 1. Effects of the oxazaphosphorines on the MOLT-4 cell viability rate. The extent of MTT conversion in MOLT-4 cells 







volume [fl ] Modal peak [fl ]
Mean cell 
diameter 
[μm]No.     Agent given Agent dose
   I D-18864   10 μg/ml
24h 1490 1442 1313 14.04
48h 1275 1218   649 13.25
   II D-17272   10 μg/ml
24h 1640 1588 1499 14.48
48h 1411 1355   649 13.71
   III D-17272 100 μg/ml
24h 1228 1158   653 13.11
48h 1082   996   649 12.59
   IV D-19575 100 μg/ml
24h 1230 1172 1011 13.18
48h 1307 1240 1085 13.44
   V Control  
24h 1148 1089   954 12.88
48h 1200 1139   970 13.06
TABLE 2. The size of MOLT-4 cells after their exposure to the oxazaphosphorine agents.
mia MOLT-4 cells. It has been found that these 
alkylating agents distinctly affected the MOLT-4 
cell viability as well as the cell size and count. 
The three oxazaphosphorines caused a decrea-
se in the metabolic activity of MOLT-4 cells, which 
manifested itself in the reduced cell viability rate. 
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Fig. 2. The volume distribution curves for MOLT-4 cells mea-
sured using the Beckman Coulter counter. The peaks on the 
left represent cellular debris, presumably apoptotic bodies 
and cell fragments, which were excluded from the analysis of 
the MOLT-4 cell volume.
Experimental group
Time intervals after cell exposure to oxazaphosphorines
24h 48h
No.             Agent given                 Agent dose
Cell count (x103)
Mean ± SD Mean ± SD
I D-18864   10 μg/ml  2, 3, 4, 5, 48h 146.70  ±   5.94
   2, 3, 4, 5, 24h
  88.43 ± 1.94
II D-17272   10 μg/ml 1, 3, 4, 5, 48h 166.94  ±   6.72
   1, 3, 4, 5, 24h
126.73 ± 1.96
III D-17272 100 μg/ml 1, 2, 4, 5, 48h   69.04  ±   2.59
   1, 2, 4, 5, 24h
  39.77 ± 1.27
IV D-19575 100 μg/ml 1, 2, 3, 5, 48h 235.52  ± 11.15
   1, 2, 3, 5, 24h
358.90 ± 5.44
V Control 1, 2, 3, 4, 48h 258.88  ±   8.61
   1, 2, 3, 4, 24h
458.99 ± 7.12
were surely responsible for the varied cell volu-
me distribution. Moreover, the oxazaphospho-
rines infl uenced a reduction in the MOLT-4 cell 
count. These cytotoxic effects can result from me-
tabolic disorders and loss of balance between the 
cell proliferation rate and cell death rate. In the 
previous investigations it has been observed that 
D-17272, D-18864 and D-19575 disturbed the 
cell cycle and cell proliferation rate as well as the-
se alkylating agents induced mitotic catastrophe 
and triggered programmed cell death in leukemic 
cell lines (MAZUR et al., 2002; 2008b, 2009, 2011; 
OPYDO-CHANEK, 2010).
D-19575 has been found to be less cytotoxic 
than D-17272, and especially than D-18864. The 
different cytotoxicity of the three oxazaphospho-
rines, observed in human leukemic MOLT-4 cel-
ls, is believed to be related to their varied action. 
The mechanisms responsible for the leukemic cell 
response to the action of the oxazaphosphorines 
have not yet been completely understood. Howe-
ver, their effects on cells are accepted to be depen-
dent on the active alkylating moiety. Phosphora-
mide mustard and acrolein are the major active 
alkylating compounds of the two oxazaphospho-
rines, D-17272 and D-18864. D-19575 contains 
the directly alkylating moiety, isophosphoramide 
mustard. The metabolism of the oxazaphospho-
TABLE 3. The count of MOLT-4 cells after their exposure to the oxazaphosphorine agents.
The functional changes occurring in MOLT-4 cells 
following their exposure to the oxazaphosphorines 
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rines has a major impact on the pharmacodyna-
mic-pharmacokinetic relationship, which can also 
infl uence the cell response to the action of these 
alkylating agents (BODY and YULE, 2000; ENGEL et 
al., 2000; ZHANG et al., 2005a; LIANG et al., 2007; 
MAZUR et al. 2011). 
To summarize, it should be underlined that 
the metabolic activity based on the amount of for-
mazan formed in the viable cells, as well as the 
cell size, are important parameters in determining 
and characterizing cytotoxicity of chemotherapeu-
tic agents, including the novel oxazaphosphorine 
agents, such as D-17272, D-18864 and D-19575. 
The results of the present study should be taken 
into account in cancer therapy.
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